Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cabozantinib trial in children and young adults with refractory sarcomas, Wilms tumor, and other rare tumors
2019-001238-32Phase 2
- Sponsor
- Cancer Therapy Evaluation Program
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in Ewing sarcoma, rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and 3 more, sponsored by Cancer Therapy Evaluation Program. Primary endpoint: Objective response rate.
02
Drugs
cabozantinib
03
Conditions
Ewing sarcomarhabdomyosarcoma (RMS)non-rhabdomyosarcoma soft tissue sarcoma (NRSTS)Wilms' tumorosteosarcoma (OS)
Beyond the preview
Go deeper on 2019-001238-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001238-32.